Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Clinical trial NCT03383575 · RECRUITING

Trial details

NCT number: NCT03383575
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Blasts 20-30 Percent of Bone Marrow Nucleated Cells Chronic Myelomonocytic Leukemia IDH2 Gene Mutation Myelodysplastic Syndrome With Excess Blasts Recurrent High Risk Myelodysplastic Syndrome Refractory High Risk Myelodysplastic Syndrome

Start date: 2018-01-17
Primary completion: 2027-02-28
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.